11 enero 2017

PharmaMar , CORPORATE PRESENTATION , January 2017 .

Puede Observarse que el Inicio de una Tercera Fase III con PM01183 para el Tratamiento de Cáncer de Mama ... es Factible y además dicho Farmaco sería el Primero de PharmaMar " Global " ...









KEY EVENTS ///  Transformative times for Pharma Mar; catalyst rich 2017 :

* Yondelis® approved in Japan for STS (9/2015); approved in the US for STS (10/2015) .
* Lurbinectedin Phase III pivotal trial initiated for SCLC (Aug. 2016) .
* Lurbinectedin interim activity analysis Phase III in platinum-resistant ovarian cancer (Aug`16) .
* Aplidin® positive data for Phase III for multiple myeloma and dossier submitted (Sept. 2016) .
* Lurbinectedin data for Phase II metastatic breast cancer (Sept. 2016) .
* Lurbinectedin Phase III in platinum-resistant ovarian cancer: recruitment completed (Oct`16) .
* Lurbinectedin license agreement in Japan (Chugai, Dec´16) .
* Update Breast cancer trial, following FDA meeting .
* Yondelis INNOVATYON (IST) interim analysis relapsed OC (2q´17) .
* Aplidin® CHMP recommendation in multiple myeloma (2H 2017) .
* Lurbinectedin Phase III data in platinum-resistant ovarian cancer (2H 2017) .
* Aplidin® OS data Phase III for multiple myeloma expected 2H17 .
*  Lurbinectedin potential start of Phase III BRCA .
*  Lurbinectedin expected publication of Phase II data as a single agent in SCLC .

La Presentación consta de 27 Paginas ... Picar en el Titular del Post .